STAT April 30, 2024
Elaine Chen

Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound, even as the pharmaceutical company struggles to make enough of the obesity drug to meet the enormous demand.

Lilly increased its adjusted earnings guidance for 2024 to a range of $13.50 to $14.00 per share, up from a prior forecast of $12.20...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Bipartisan scrutiny of health care mergers
Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA’s 2024 Update
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
AZ plots $1.5B antibody-drug conjugate plant in Asia
STAT+: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality

Share This Article